{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:23:48Z","timestamp":1790792628680,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.msard.2020.101961","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T03:21:33Z","timestamp":1580354493000},"page":"101961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use"],"prefix":"10.1016","volume":"40","author":[{"given":"James D","family":"Triplett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srimathy","family":"Vijayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivarajani","family":"Rajanayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Tuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan G.","family":"Kermode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.101961_bib0013","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1756285614540224","article-title":"Extended interval dosing of natalizumab: a two-center, 7-year experience","volume":"7","author":"Bomprezzi","year":"2014","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"10.1016\/j.msard.2020.101961_bib0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM199807303390501","article-title":"Pregnancy in multiple sclerosis group. rate of pregnancy-related relapse in multiple sclerosis","volume":"339","author":"Confavreux","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1016\/j.msard.2020.101961_bib0014","first-page":"1","article-title":"UK consensus in pregnancy in multiple sclerosis: \u201cAssociation of british neurologists\u201d guidelines","volume":"0","author":"Dobson","year":"2019","journal-title":"M Pract Neurol"},{"key":"10.1016\/j.msard.2020.101961_bib0002","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12883-016-0674-4","article-title":"Evaluation of pregnancy outcomes from the tysabri (natalizumab) pregnancy exposure registry: a global, observational, follow-up study","volume":"16","author":"Friend","year":"2016","journal-title":"BMC Neurol"},{"issue":"7","key":"10.1016\/j.msard.2020.101961_bib0003","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","article-title":"Natalizumab use during the third trimester of pregnancy","volume":"71","author":"Haghikia","year":"2014","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.msard.2020.101961_bib0005","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.msard.2020.101961_bib0016","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10928-017-9514-4","article-title":"Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis","volume":"44","author":"Muralidharan","year":"2017","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.msard.2020.101961_bib0008","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jns.2018.11.026","article-title":"Natalizumab exposure during pregnancy in multiple sclerosis: a systematic review","volume":"396","author":"Peng","year":"2019","journal-title":"J Neurol Sci"},{"issue":"12","key":"10.1016\/j.msard.2020.101961_bib0007","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1177\/1352458517728813","article-title":"Natalizumab during pregnancy and lactation","volume":"24","author":"Proschmann","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.msard.2020.101961_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"10","key":"10.1016\/j.msard.2020.101961_bib0006","first-page":"e823","article-title":"Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: fetal risks","volume":"90","author":"Portaccio","year":"2018","journal-title":"Neurology"},{"issue":"2\u20133","key":"10.1016\/j.msard.2020.101961_bib0009","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1387\/ijdb.082773hs","article-title":"Receptor-mediated uptake and transport of macromolecules in the human placenta","volume":"54","author":"Schneider","year":"2010","journal-title":"Int J Dev Biol"},{"key":"10.1016\/j.msard.2020.101961_bib0015","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00415-015-7655-1","article-title":"Body weight-based natalizumab treatment in adult patients with multiple sclerosis","volume":"262","author":"Tanaka","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2020.101961_bib0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/bdrb.20190","article-title":"Embryo\/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor","volume":"86","author":"Wehner","year":"2009","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.msard.2020.101961_bib0011","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/bdrb.20193","article-title":"Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor","volume":"86","author":"Wehner","year":"2009","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"issue":"8","key":"10.1016\/j.msard.2020.101961_bib0012","first-page":"885","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"JNNP"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820300377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820300377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:47:00Z","timestamp":1761900420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820300377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":16,"alternative-id":["S2211034820300377"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.101961","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.101961","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101961"}}